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Abstract
The intention of this chapter is to provide an overview of how pharmacokinetics, also 
termed PK, is applied in early drug development. While there are many readily avail-
able printed and web accessible sources on pharmacokinetics, its technical terms, model 
definitions, and calculation methods; how the science of pharmacokinetics is used in 
specific situations, namely early drug development are not as readily covered. In fact, the 
reader will see that the continual theme in this chapter is that a small amount of pharma-
cokinetic data and its interpretation in the first nonclinical or clinical study is important 
in obtaining additional pharmacokinetic, safety, and efficacy information for the next 
study. The role of PK in the three phases of clinical drug development is described as 
well as the types of early Phase 1 studies where PK determinations are important. The 
PK measurements in the first in humans study (FIH) provide a tentative confirmation of 
safety at the measured exposures from the tested dose levels. Even if exposures from a 
given dose change due to food-effects, drug–drug interaction, drug-disease interactions, 
or use in a special population, safety can be assessed by bridging these results to the 
initial safety or efficacy exposures.
Keywords: pharmacokinetics, drug development, compartmental modeling,  
non-compartmental pharmacokinetics, non-clinical pharmacokinetics
1. Introduction
The intention of this chapter is to provide an overview of how pharmacokinetics, also termed 
PK, is applied in early drug development. Since, PK is defined as the study of the effects of 
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a living organism on an administered drug, the majority of pharmacokinetic studies involve 
the measurement of a specific compound in an easily sampled physiological fluid, like blood, 
plasma, serum and on occasion, in saliva. Excreted substances are also measured in urine or 
feces. In some rarer situations, measurements are made with more invasive sampling meth-
ods, such as a tissue biopsy, cerebral spinal fluid, bronchoalveolar lavage fluid, or middle ear 
effusion fluid. Regardless of the sample type, the measured concentrations are regarded as 
indicative of the concentrations at the specific site of action for the drug. Even excreted drug 
data can be used to describe the PK within the body; drug excretion rates into urine are rec-
ognized as proportional to plasma concentrations at midpoints of the collection interval, and 
amounts of drug in urine and feces can give some idea of excretion pathways. Series of drug 
concentrations measured in biological fluids over an adequate amount of time give the phar-
macokinetic scientist a ‘window’ into the body, and by analyzing the time course of concen-
trations, information on the unseen drug in the various body compartments can be inferred. 
Thus, applied pharmacokinetics are useful in various types of pharmacological evaluations, 
be it for academic purposes, clinical research (inside and outside of drug development), or in 
clinical medicine (individualized dosing and therapeutic drug monitoring) [1–3].
While there are readily available printed and online materials on pharmacokinetic topics such 
as its technical terms, model definitions and calculation methods [4–5]; there are some gaps 
when it comes to how the science of pharmacokinetics is used in drug development. Several 
authors however, have touched on various aspects and a reader of this chapter may gain addi-
tional knowledge by consulting them [6–8]. Most healthcare workers and scientists are rela-
tively familiar with the clinical pharmacology and medicine package inserts which include a 
pharmacokinetic section of an approved drug’s labeling. This section of the package insert gives 
the general information that has been gleaned from large amounts of research and helps the 
practitioner or scientist understand the general absorption, distribution, metabolism, and elimi-
nation of a given therapeutic agent. In essence, this is only a short summary of what is known 
about this drug. Not readily apparent from the short summary is the role that pharmacokinetics 
had from the start of a drug’s development through its approval journey. Through the applica-
tion of pharmacokinetics, the maximum information can be extracted from data when only a 
few subjects are available as in a first in human (FIH) clinical study and then this information 
is applied to the design and interpretation of the next study during the drug’s development 
phase. Furthermore, even before the first clinical human study is conducted, pharmacokinetic 
and toxicological data from animals can be used to predict human pharmacokinetics and to 
assist in the determination of a safe starting dose and the optimal study design. In fact, the 
reader will note that the continual theme in this chapter is that pharmacokinetic data and their 
interpretation in the first study is important in obtaining additional pharmacokinetic, safety, 
and efficacy information a subsequent study, and so on, throughout the drug development 
process. In the following pages, various types of PK evaluations and/or studies are described.
2. Pharmacokinetics and early drug development
Clinical drug development, meaning drug research in human subjects, is generally described 
in three phases, each comprised of a number of different clinical studies, Phases 1, 2, and 3, (see 
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Figure 1) [9, 10]. However these three phases do not encompass the entirety of the research for 
any given new drug: nonclinical research starts prior to Phase 1, and post-marketing studies 
(sometimes referred to as Phase 4) continue after Phase 3 and medicines regulatory agency’s 
approval. Once a new chemical entity (NCE), a new molecular entity (NME), a new biological 
entity (NBE), a new active substance (NAS) or a new therapeutic entity (NTE) [11], also called 
investigational product (IP), or in general for this chapter, a new drug, is identified and the min-
imum in vitro and animal data are gathered, and after filing an application with the appropriate 
regulatory agency, a promising substance can start clinical research [12]. For sake of clarity, an 
overview of the three phases of studies is given below and the roles of PK data are highlighted.
Phase 1 studies (some exploratory studies are also called Phase 0) in clinical drug develop-
ment are described as the initial introduction of the drug into humans, in small numbers of 
healthy subjects (if appropriate), starting at lower doses and escalating as safe to therapeutic 
ranges and super therapeutic ranges if possible. The reasons for studying higher doses, if 
deemed safe to do so, can be multi-faceted. Confirming safety at higher doses helps deter-
mine a margin of safety around the efficacious doses, and aids in determining the clinical rel-
evance of any drug–drug- and drug-disease-interactions, or special population differences 
that may be elucidated later. Pharmacokinetics over a wider range leads to the ability to 
correlate drug effects (therapeutic or adverse) with drug exposure, and to characterize these 
relationships [13]. The aforementioned safety margin also allows the drug sponsor some 
flexibility in determination of the final marketed dose if necessary. Phase 1 also includes spe-
cific studies designed to study special populations, such as the elderly, children, in people 
Figure 1. Phases of drug development built on pharmacokinetics.
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with hepatic or renal impairment. In these studies, pharmacokinetic endpoints are the pri-
mary goal, allowing relatively small studies (low numbers of subjects) to inform the future 
Phase 2 and 3 studies and marketing after approval. The results of these studies are reflected 
in the approved drug’s labeling, where warnings about the use in certain disease-states or 
dosage adjustments are communicated.
In Phase 2 studies of clinical drug development, the objective is not only to determine that 
a drug continues to be safe but that it remains to be safe when used in patients with the 
disease it is intended for to treat. The information gathered in Phase 2 serves the dual pur-
pose of studying safety and efficacy while providing proof to the sponsor that the drug is 
worthy of further development. The pivotal Phase 2 study for continuation of Phase 2 and/
or starting Phase 3 is often called ‘Proof of Concept (POC).’ The value of PK measurements 
in Phase 2 adds another layer of understanding how the body processes the drug; these 
studies determine differences in PK data between categories of patients, namely those with 
the targeted disease and normal healthy volunteers. Sometimes patients will have higher or 
lower exposures of a drug due to the difference in ability to absorb a drug, or the drug may 
be eliminated differently due to the disease state. In general, the more the patient is affected/
weakened by the disease, the more PK will differ from healthy subjects. Knowledge of the 
PK in the patient population forms a bridge to knowledge of safety and perhaps efficacy 
gathered in Phase 1. Phase 2 PK facilitates any need for dose adjustments to achieve safety 
or efficacy. PK correlations with efficacy can begin in earnest once patient data is available; 
this data along with the Phase 1 data is modeled and simulations using those models assist 
in choosing the Phase 3 dose ranges.
Phase 3 in clinical drug development consists of several large studies in patient populations 
designed to collect further safety data, to observe possible adverse events which occur only 
rarely, to continue to evaluate efficacy and compare with current therapies for the indication, 
and to guide its use once approved and on the market. However, clinical research does not 
necessarily come to a halt at the end of Phase 3. After approval and marketing, additional 
studies may be run by the sponsor to establish marketing claims and to seek new indica-
tions. Adverse event data are continually collected to identify even rarer adverse events not 
uncovered in Phase 3. Phase 3 PK data is usually performed only as a few samples in many 
subjects or complete profiles in a subset of subjects; this data is for confirmatory purposes, 
used in correlation with efficacy or adverse events. This data is added to the ongoing model-
ing (discussed later in Section 3.1) to discern sources of variability in the PK data from the 
patient population.
The above descriptions of each phase of drug development may seem as though each phase 
precedes sequentially, one starting after the end of the other; however this may not always be 
the case. While typically the end of Phase 2 commences the beginning of Phase 3, the other 
phases may overlap in time. This is mainly to conserve research and development resources. 
For instance, the longer animal studies and reproductive toxicity studies may not run until 
the results are needed to support the Phase I and II studies for drugs that may require longer 
treatment durations or research in women of child-bearing potential (WOCBP),  respectively 
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[14]. A thorough Phase I study to determine QTc prolongation and potential for cardiac 
arrhythmias (if not characterized already in earlier studies) should not be run until some idea 
of the clinical doses and exposures are determined and after a few studies have shown some 
promise for the drug’s future approval.
3. Pharmacokinetic analyses
Pharmacokinetic analyses types can be broken into two general approaches: compartmental 
and non-compartmental. Non-compartmental analyses are a series of calculations that esti-
mate the exposures and elimination properties of a drug with very few assumptions about 
the particular mechanisms involved. Non-compartmental exposure parameters (such as area 
under the concentration-time curve (AUC) and the maximum exposure (Cmax) can be cal-
culated and are interpretable when no other PK information is available; these parameters 
indicate the amount of drug in the body and for how long it is there, and the peak concentra-
tion that is achieved.
Compartmental methods can be described as the determination of a mathematical expression, 
or model, which adequately describes the PK of a given drug. On the most basic level, these 
models consist of the mathematical description representing the body as one or a series of 
hypothetical volume compartments which drug distributes into and out of, or from which it is 
eliminated. These models not only describe the PK properties of a drug, but can be predictive 
of PK at different dose levels or administration conditions. Complex models aid in the eluci-
dation of smaller processes which make up the PK in its entirety, such as the rate and capacity 
of the different metabolism pathways involved in a drug’s elimination.
3.1. Compartmental pharmacokinetics
The process of fitting PK data to a given mathematical description, or model, is known as 
compartmental modeling. This modeling is carried out with specialized software applica-
tions and [15, 16] Figure 2 shows the simplest one-compartment PK model where drug is 
introduced by an intravenous bolus injection into a representative volume compartment and 
the differential and integrated equations that can be fitted to actual data to determine the 
values of the constants as defined. Multiple-compartment PK models, such as a 2-compart-
ment model, or a 3-compartmental model, commonly describe a concentration-time course 
adequately, but more complex models may contain more compartments. The mathematical 
models are based on the processes which move drug into or out of the compartments; these 
may be a constant rate of infusion or elimination (a zero-order kinetic process) or concentra-
tion-driven diffusion processes (first-order kinetics) or by saturable active transport or meta-
bolic processes (Michaelis–Menten kinetics), or combinations thereof [17–19]. The intention 
of a compartmental model can be as straightforward as to find the simplest model which 
describes the PK and predicts drug exposures under new conditions, like a higher dose, or 
when administered in multiple doses over time, or when administered under a different route 
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of administration. However, sometimes the purpose may be more complex, to elucidate addi-
tional processes such as metabolism mechanisms or drug effects, and these models may con-
tain many compartments.
Compartmental modeling in the very early stages of drug development might be used for sup-
plemental information or to set the initial assumptions for further additional modeling later 
in the drug development program; known as population pharmacokinetics [20]. Population 
pharmacokinetics (termed in the industry as ‘Pop PK’) is the systemic analysis of compiled 
data from specific studies or from the entire drug development program. These analyses are 
used to better understand the concentration-time course of the drug and to explain potential 
sources of PK variability. These models take either sparse PK data (limited numbers of sam-
ples) from large numbers of subjects and patients, or both, and/or rich sampling data (full serial 
PK sampling profiles) from early PK studies, and often incorporate development of individual 
patient covariates (e.g., BMI, race, genotypes, concomitant medications, disease status, etc.) to 
predict exposure and effects in individual patients. Figure 3 shows that this type of analysis 
not only allows individual patient predictions, but also provides average PK parameters for 
the population. A population PK approach is also useful in clinical research situations where 
Figure 2. One-compartment pharmacokinetic model. graphic presentation of a one-compartment PK model with an 
intravenous bolus injection of dose (D) into a single central compartment of volume V, with a first-order elimination rate 
of kel. Where Cp is the concentration in the compartment which decreases over time (t). The model is described by a 
single differential (1) dCp/dt = D/V × (−kel). The integrated Eq. (2) is Cp = (D/V) e−kelT. Secondary parameter CL (clearance) 
is calculated by Eq. (3) CL = V*kel.
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 ethics, patient safety, and/or patient comfort limit the number of PK samples that can be col-
lected, such as in neonates, pediatrics, and patients with advanced diseased states.
Compartmental and non-compartmental (to be discussed Section 3.2) PK parameter estimates 
tend to vary within (intra-patient variability) and between individuals (inter-patient variabil-
ity), with some drugs having more variability than others. Commonly these estimates vary by 
at least ±15–20% in normal volunteers which can make interpretations challenging, especially 
when only a few subjects have been evaluated. PK estimates in patient populations typically 
have even more variability. Population pharmacokinetics, once data is obtained in enough 
patients and subjects, can help identify and characterize the various sources of variability.
3.2. Non-compartmental pharmacokinetics
Non-compartmental pharmacokinetics include a number of calculations performed with a 
series of PK samples usually with plasma- or serum-concentration-time data. These param-
eters provide a model-free description of how the drug is dispersed and eliminated from the 
body. These types of analysis can be done very quickly with limited numbers of subjects, 
where in compartmental or population modeling can take quite some time to build a model. 
Since no assumptions of which type of compartmental model fits the data best are required, 
a non-compartmental approach is applied in most Phase I PK studies, and is quite useful in 
Figure 3. Population pharmacokinetics. Population model predictions (solid line) with 95% CI (shaded area) with 
observed data (circles).
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understanding the drug and indexing its exposure, determining the clinical dose, and design-
ing the final marketed dosage form. The PK parameters obtained from non-compartmental 
analyses are illustrated in Figure 4. Cmax, the peak concentration gives researchers a maxi-
mum drug exposure and is also dependent on the absorption rate for extravascular admin-
istrations, while the time of Cmax, Tmax, is also indicative of the rate of absorption, but one 
must understand drug elimination is also occurring at this time. The log-linear slope at the 
end of the concentration-time curve can be used to estimate the terminal elimination rate 
constant and the terminal elimination half-life, assuming the curve is well characterized and 
the PK exhibits first-order elimination. Too short of a sampling interval or limitations of the 
bioanalytical method may result in missing the terminal elimination phase, so in some cases 
this slope may be more representative of drug distribution. By calculating an area under the 
concentration-time curve, called AUC, an index of overall exposure is obtained, and this 
exposure is independent of the shape of the curve, be it the sharp increase of an intravenous 
injection with a high Cmax, or lower concentrations observed over a longer amount of time 
after a slow-release oral formulation. From AUC calculations and the terminal elimination 
rate constant, estimations volume of distribution and clearance, abbreviated as V and CL, for 
intravenous doses, or after extravascular doses abbreviated V/F and CL/F, unadjusted for the 
bioavailable, F, can be made.
Figure 4. Non-compartmental model parameters. Cmax = peak concentration, Tmax = time of peak concentration, 
kel = negative terminal slope from ln concentration versus time regression, T1/2 = 0.693/kel (apparent terminal elimination 
half-life) AUC0-t = Area un the concentration-time curve from 0 to the last quantifiable concentration estimated by the 
trapezoidal rule, AUC0-∞ = Area under the curve extrapolated to infinity (AUC0-t + Cp(t)/kel, CL/F = Dose/AUC0-∞ 
(after a single dose), V/F = apparent volume of distribution after an extravascular dose, calculated by CL/F / kel.
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4. Nonclinical pharmacokinetics
Before an investigational drug is ever administered to a human subject, an immense amount 
of animal and in vitro data are gathered. For example, tests in cell lines and/or animal models 
are used to determine the potential of the drug’s therapeutic action. Other in vitro tests can 
screen for safety, such as in hERG (Human ether-a-go-go Related Gene) expressed cells, to 
determine a drug’s potential to interact with the potassium channel, IKR, and cause cardiac arrhythmias [21]. Ultimately, single- and repeat-dose toxicity studies, also called ‘toxicoki-
netic or TK’ studies, in rodents and at least 1 non-rodent species are needed to support the 
investigation of the drug in humans [14]. While these studies are mandated by regulatory 
agencies, they are also useful in the design of the FIH study for a drug’s development pro-
gram. Depending on the type of drug and its apparent risk, several methods of determin-
ing the starting dose based on observed toxicity at dose levels can be used. These methods 
range from simple adjustment and allometric scaling of the non- observed adverse effect 
level (NOAEL) in the most sensitive animal species studied, with a safety margin [22]. to 
complex scaling modeling to predict human exposures from animal data. For particularly 
risky compounds, the starting dose is sometimes carefully based on the minimum biologi-
cally active concentration and its associated dose level, also called the minimum effective 
dose (MED) [23].
Sometimes detailed PK in animals is available, but generally the PK data from animal 
studies come from the toxicoketinetic studies. In these studies, the goal is to determine 
exposure for correlation with toxicity, but qualitative expectations of how the drug 
will behave in a human are conceived. It would be expected, but not guaranteed, that a 
quickly absorbed and quickly eliminated drug would also act similarly in humans. Useful 
predictions of a drug’s human PK can be made using computer modeling techniques, 
called PBPK (physiological based pharmacokinetic modeling) interspecies scaling, which 
take different species’ capacities of absorption, body distribution, and metabolic/excre-
tion into account and simulate PK concentrations based on an analogous human model 
[21, 24–26].
Nonclinical studies are also important for providing an idea of the mechanism of the drug’s 
metabolism, whether any cytochrome P 450 enzymes are involved, and identification of 
metabolites which could be important in humans [27]. Metabolites identified in animals 
that represent 10% of drug circulating material need to be monitored in toxicology studies 
and later in clinical studies if still a significant metabolite, is disproportionately produced in 
humans, or if it is biologically active [28]. In vitro experiments with hepatic enzyme prepara-
tions and various chemical probes identify which CYP 450 enzymes are potentially active 
in the metabolism of a drug. Once these are determined, potential drug-drug interaction 
pathways are realized; this information is then used to design Phase I drug-drug interaction 
studies to characterize the clinical significance of these possible interactions in. In vitro experi-
ments also provide the identities of drug-transporters which may move drug into or out of 
various organs in the body. Drug–drug interactions can also be mediated by inhibition or 
competition within these transporter systems [29].
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5. Early clinical studies with primary endpoints of safety
Earlier this chapter described the primary objective of Phase I as determining safety in a small 
number of subjects before the introduction of the drug into patients. This remains true, but for 
the purposes of this chapter, Phase I studies will be described as studies whereby safety mea-
surements are the primary endpoint (or finding) and where primary endpoints are PK-related.
5.1. First in human studies
The main purpose of the first in human clinical study (FIH) for a drug is to test that it is safe, 
meaning that subjects are monitored for signs of toxicity, especially those indicating risk of 
mortality or morbidity. Tolerability, the ability of a patient to use the drug for its intended 
indication, without unacceptable, non-life-threatening adverse events that would require dis-
continuation of treatment, is also an important consideration. Risk-to-benefit ratios are consid-
ered when determining the required tolerability and risks of toxicity; a drug for a life-saving, 
unmet clinical need, such as cancer, would be considered for approval even if it carries more 
risk than a drug for a self-limiting or non-life-threatening disease, such as the common cold. 
From the animal data discussed above, researchers have a good idea of the types of toxicity 
and at what exposures they may occur for a given drug, yet the first human study is critical in 
confirming the drug’s potential for toxicity in a human. PK in a FIH is therefore very informa-
tive, telling us not just if toxicity occurs, but at what exposure that toxicity correlates with.
5.2. Single-ascending-dose studies (SAD)
Typically, the FIH study is the single-ascending dose study, where small numbers of subjects 
are dosed carefully with either the drug or placebo, and safety is monitored by recording 
adverse events, clinical laboratory measurements, vital signs, electrocardiograms, and addi-
tional tests depending on concerns raised in the animal studies or from the known phar-
macology. Once a small dose is administered and considered to be safe, then a higher dose 
(typically 2–3 times higher than the starting dose) is administered to a new group of subjects 
which is then considered before a higher yet dose is given. The escalation schedule for ascend-
ing doses needs to be considered carefully, using smaller increments of increase with higher 
risk drugs, the predicted therapeutic range for the drug, and the levels of exposure where tox-
icity was seen in animals [30]. Study protocols for drugs considered to be high risk or of nar-
row therapeutic range may have stopping criteria based on PK as well as safety. Some study 
protocols will set an upper limit on PK parameters of exposure that are not to be exceeded 
in the study. The escalation schedule or planned doses may be revised depending upon the 
outcome of the previously dosed groups. Unexpected toxicity may require lowering the dose 
and subsequent doses; lower than expected exposure (if assessed before the study finishes) 
might require increasing the planned doses or accelerating the dose escalation.
The design of the FIH study will incorporate animal data or interspecies scaling predic-
tions to determine when and how long blood (usually plasma or serum) should be sampled 
for PK measurements. Ideally, to characterize a PK profile, sampling would be optimized 
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to capture absorption rates, peak concentrations, distribution and elimination phases, and 
would minimally be 2–3 times the elimination half-life, preferably 4–5 times the elimination 
half-life. Sometimes at lower dose levels this is difficult due to the limitation of the bioana-
lytical method used to measure drug concentrations.
When PK information is needed for dose escalation a common practice is to perform interim 
PK analyses as the study progresses, where the PK is examined in one group before proceed-
ing to the next higher dose level group. This is a time sensitive process where careful planning 
with logistics between the clinic conducting the study, sample shipment, the laboratory ana-
lyzing the samples, the scientist performing the PK calculations, and sometimes a data safety 
monitoring board (DSMB) who will review the data and make a determination along with the 
sponsor and principal investigator in charge of clinic conduct. Once at least two dose levels 
have been administered, the scientist will use the data obtained to date in order to determine 
if the increase in exposure is proportional to the increase in dose (dose proportionality) and if 
so to predict what exposures might be at the next dose level, given that dose proportionality 
continues to the next dose. If dose proportionality is not seen (the PK may be described as 
‘nonlinear’) [31], and the increase is higher than proportional to the increase in dose, escala-
tion to higher dose levels should proceed with caution, as saturation of a metabolic or elimi-
nation pathway could lead to sharp increases in PK concentrations with only a small increase 
in dose. If PK concentrations are less than proportional to the increase in dose, indicating a 
saturation in the absorption process, then the dose escalation schedule may need to be revis-
ited in order to achieve target exposures.
5.3. Multiple-ascending-dose studies (MAD)
PK information gained in the single-ascending dose assessment of a drug development pro-
gram is used further in the design of the next clinical study, which for most drugs is the 
multiple-ascending dose study. Because most drugs need to be given repeatedly over time, 
safety information for continuous use is needed. In this study, the drug is administered for 
the number of doses required (based on the single-dose PK) to reach steady-state levels, the 
highest exposure a given drug regimen will achieve, where the given drug exhibits first-order 
elimination (Figure 5). Again, the main purpose of the study is to determine safety at maxi-
mum exposures, but PK at these exposures is applicable to the design of the next study in 
the drug development program. Steady-state levels depend upon the half-life, the dose, and 
how often the drug is given (also called the frequency of administration). If PK properties 
after a single dose are known, then the number of repeated doses given at equal intervals for 
a duration of approximately 5 times the half-life will reach predictable steady-state levels. 
Confirmation of steady-state in this type of study is usually assessed by determining if trough 
(predose) concentrations for the last few doses are approaching a constant value; [32] this also 
helps confirm that the half-life observed after single doses was based upon the elimination 
phase, that the PK is indeed first order, and is or is not ‘linear’ over time. Linear or nonlinear, 
the single- and multiple-dose studies in Phase I not only determine safety at a certain expo-
sure, but the relationship of dose to exposure, leading to predictability to adequately achieve 
target exposures further along in Phases II and III.
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It should be noted that the single- and multiple-dose studies are not always run in two sepa-
rate studies. Depending upon the sponsor, type of drug, its PK qualities, and how much 
dose-limiting toxicity is expected, these assessments may all be performed under a single 
study protocol [33]. These studies are termed SAD/MAD studies, and may be designed in 
two parts, a single-dose and a multiple-dose part to follow when the first is completed or 
partially completed. Sometimes the study is designed for the sequential groups to get a single 
dose followed by a washout period where they are monitored, and then the same group will 
be started on multiple doses at the same level as the first dose for a period of time expected to 
reach steady state. Safety and or PK is examined for that group, and if deemed safe, then the 
dose is escalated in the next group.
6. Early clinical studies with primary PK endpoints
Once the SAD and MAD studies have confirmed acceptable safety to proceed further into 
Phase 1, several types of studies are conducted where PK endpoints are the primary objec-
tive, and continued collection of safety data is only secondary. These studies determine the 
effects of other drugs, diseases, and patient qualities on the PK of the drug in relatively small 
numbers of subjects, reducing the risk to patients in the Phase 2 and 3 studies, and ultimately 
informing the marketed use of the drug.
Figure 5. Single dose and steady-state pharmacokinetics.
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6.1. Food effect studies
One of the most important PK studies for an orally administered (and sometimes with inhaled 
drugs where some drug is swallowed) is the food-effect study. An experienced clinical pharma-
cokineticist will say that the absence of a food effect on the rate or extent of a drug’s absorption is 
rare, and looking at many drugs, most have some difference in absorption between fed and fasted 
states. Food-effect information is typically not clear from nonclinical studies in most programs, 
as animals are usually fed ad libitum or on a regular schedule in toxicology studies. A food effect 
can be somewhat predicted for a specific drug, with knowledge of its solubility, its lipophilicity, 
and pH dependence on ionization and partitioning, but a human study is required to confirm the 
extent of the food-effect [34]. Since food in the stomach can affect gastric pH and potentially bind 
to a drug, and food and/or its fat content can affect gastric emptying time, the probability of some 
effect on absorption is high. A food effects range from very subtle changes in just Tmax or Cmax, 
to several-fold increases or decreases in overall exposure, to ultimately where a lipophilic drug 
might be totally unabsorbed without a minimum of dietary fat. PK parameters, especially Cmax, 
Tmax, and AUC, can characterize this difference with only a single dose of drug, in a crossover 
study design, where each subject is administered the drug with and without food. Many drug 
development programs strive to get this information as early as possible to determine the opti-
mal dosing conditions, and is often part of the SAD, MAD, or SAD/MAD study protocol.
The purpose of the food-effect PK study is to determine if a difference occurs, and if this dif-
ference is clinically significant. If found to be clinically significant, that is that food decreases 
absorption enough to make it less effective, or that it increases absorption enough to cause 
toxicity. If the PK shows a clinically significant food effect, adjustment of the therapeutic dose 
and/or instructions on how the drug should be administered will be included in the approved 
drug labeling. The type of drug is also important in this decision, as commonly food may 
delay Tmax and decrease Cmax, but if only the extent of exposure (AUC) is important for the 
drug’s efficacy, then the food effect might not be clinically relevant.
6.2. PK studies in special populations
Once the pharmacokinetic behavior of a drug and its initial safety is confirmed in normal 
healthy volunteers in the early Phase 1 studies, additional Phase 1 studies are performed to 
determine if PK differs in various special populations [35]. A simple special population study 
can be used to bridge the entire drug development program of a drug for one population to 
apply to another population. An example would be a drug developed in Japanese populations 
that is then intended to also be marketed in the US. Most small molecule drugs are investigated 
in subjects with hepatic or renal impairment [36, 37], and depending on the drug’s intended 
use, additional studies in elderly, obese, certain racial/ethnic groups, or others are performed. 
While safety is monitored in these studies, the PK endpoints allow inference of safety and 
efficacy that has been determined in previous studies. In other words, if age does not appear 
to affect the PK of a drug, it is well accepted that the previous safety findings will also likely 
apply, in general, if the drug is used without regard to age. In hepatic and renal impair-
ment, plasma proteins, such as albumin, can be lower than in healthy subjects, so free drug 
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concentrations are often examined to determine if any PK differences are related to the differ-
ences in binding, or if increased free drug concentrations might result in any drug effect differ-
ences [38]. These studies are often single-dose PK studies in the special group and in healthy 
volunteers of similar demographics. PK parameters of exposure are key in the between-group 
comparisons; however, elimination rates and absorption rates are also important.
6.3. Drug-Drug interaction studies
As mentioned previously, nonclinical studies are key in screening a drug for potential drug–
drug interactions (DDIs). Once the cytochrome P450 enzymes and transporters for which a 
new drug is a substrate, an inhibitor, or can induce expression, are identified, clinical studies 
are performed to confirm, quantitate, and determine clinical significance of any DDI. It would 
be tedious and cost prohibitive to test every possible DDI, so appropriate probes [39] (other 
drugs which are known CYP or transporter substrates, inhibitors, or inducers) are chosen 
to be co-administered and PK measured to determine if a clinically relevant DDI through a 
specific metabolism or transporter pathway exists [40]. Without PK measurements in this type 
study, it would take large numbers of subjects to study a drug–drug interaction with safety 
endpoints only, however with PK, a small number of subjects’ exposures to one or both drugs 
can determine if there is a safety risk by examining previous PK measurements and corre-
lated safety findings. These study designs may differ depending upon the potential interac-
tion, but usually the drug under development is dosed to steady-state at a therapeutic dose. 
Often these studies are conducted with 12–24 healthy subjects confined to a research clinic, 
and consist of a fixed treatment sequence for all subjects. An example of a common design 
would be where the probe drug is administered alone, followed by a washout period, then the 
multiple doses of the investigational drug are given until steady-state levels are reached, then 
the probe drug is co-administered. PK of the probe drug is measured to determine if the PK 
is affected. The sequence could be reversed if the investigational drug is hypothesized to be 
affected by the probe drug. Two-way DDI designs are also used to determine the two drugs 
affect each other. The primary PK endpoints are generally Cmax and AUCs to determine if 
peak or overall exposure differ due to a DDI, but Tmax and elimination rates are helpful in 
determining if the mechanism is due to decreased metabolism or a change in absorption.
Interpretation of the PK data for these studies is often straightforward; if a DDI increases 
exposure of a drug, depending upon its safety profile, to a degree that toxicity could develop, 
or decreases exposure enough that efficacy would be lost, then warnings will be issued in the 
approved labeling. Occasionally unexpected results in these studies are seen such that relat-
ing the results to specific enzymes or transporters becomes difficult, especially when multiple 
enzymes or unknown transporters are involved. In such instances, the characterization of 
DDIs helps in the design of Phase 2 and 3 studies where a study protocol excludes patients 
taking certain medications, and allow the safe investigation in patient populations.
6.4. Radiolabeled drug studies
A concern for a small molecule drug in development is the question of whether the drug is 
readily removed from the body completely, and how that complete elimination occurs. Less 
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so is whether the drug might accumulate in specific tissues in an undesired way. Along with 
the question of how a drug is eliminated, another question is what metabolites are formed and 
how are they excreted. These questions are answered with PK studies using radiolabeled drug, 
which is commonly called the ‘ADME’ or ‘Mass Balance’ study [41]. These studies usually 
include only 6–8 healthy males given a single dose and confined to a research clinic until most 
of the drug-related radioactivity has been recovered in urine and/or feces. An easily measur-
able dose of the study drug is administered along with a small amount of the drug that is radio-
labeled, usually with carbon 14 (14C), and sometimes with tritium (3H). PK of unlabeled drug 
and radioactivity in blood and plasma are measured, and total radioactivity are measured in 
complete urine and feces collections. These studies can be quite long, as the measurements con-
tinue and subjects are confined until only small amounts of radioactivity are excreted in urine/
feces each day. The advantage of measuring radioactivity is that it represents the total amounts 
of drug-related material in blood/plasma, urine, and feces. The drawback for total radioactivity 
measurements is that it is non-specific. However, comparing unlabeled unchanged drug levels 
and total radioactivity levels allows the scientist to gauge the amount of metabolites that are 
circulating and their collective PK behavior. A second aspect of these studies are the determina-
tion of the identity of the metabolites and their quantities in plasma, urine and feces by radio 
chromatography, also known as metabolic profiling. Since the drug was radiolabeled, different 
chemical entities resulting from the breakdown of the drug in the body can be identified as 
they will also be radiolabeled. The amounts of radioactivity recovered in urine and feces are 
totaled, and summed, for the determination of mass balance, i.e. the amount of radioactivity 
administered is expected to be nearly equal to the radioactivity excreted.
The distribution of the drug and its metabolites (as measured by radioactivity) into erythrocytes 
is another important aspect of the ADME study, and goes along with the question of drug accu-
mulating in tissues. By measuring radioactivity concentrations in whole blood and in plasma, 
it is possible to determine if the drug-related material binds to or collects in erythrocytes [42].
7. Summary
The above overview has shown that pharmacokinetics is an integral part of drug devel-
opment, and a critical part of early drug development. At the beginning of Phase 1 in the 
development program only animal data is available; hence, what is known through phar-
macokinetic measurements in those animal studies is applied in designing Phase 1 human 
studies. This chapter outlined the importance of pharmacokinetic data in drug development 
overall and in specific types of early clinical studies. The PK measurements in the FIH study 
provide confirmation of safety at the measured exposures from the tested dose levels. Even if 
exposures from a given dose change due to food-effects, drug–drug interaction, drug-disease 
interactions, or use in a special population, safety can be associated and risks assessed by 
bridging these results to the initial safety or efficacy exposures. Throughout the drug devel-
opment program, pharmacokinetics is a tool used to link exposure to efficacy and safety, and 
it assists in the determination of dosages of marketed drugs; for this reason, PK data are an 
important part of the information provided to clinicians.
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